• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy.

作者信息

Suzuki Kumi, Babazono Tetsuya, Murata Hidekazu, Iwamoto Yasuhiko

机构信息

Division of Nephrology and Hypertension, Diabetes Center, Tokyo Women's, Medical University School of Medicine, 8-1 Kawadacho, Shinjukuku, Tokyo 162-8666, Japan.

出版信息

Diabetes Care. 2005 Aug;28(8):2038-9. doi: 10.2337/diacare.28.8.2038.

DOI:10.2337/diacare.28.8.2038
PMID:16043754
Abstract
摘要

相似文献

1
Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy.
Diabetes Care. 2005 Aug;28(8):2038-9. doi: 10.2337/diacare.28.8.2038.
2
Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.尿 L-FABP 与贫血：尿标志物在 2 型糖尿病中的不同作用。
Eur J Clin Invest. 2010 Feb;40(2):95-102. doi: 10.1111/j.1365-2362.2009.02220.x. Epub 2009 Nov 11.
3
Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.匹伐他汀对早期糖尿病肾病患者尿肝型脂肪酸结合蛋白水平的影响。
Diabetes Care. 2005 Nov;28(11):2728-32. doi: 10.2337/diacare.28.11.2728.
4
Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.血管紧张素II受体拮抗剂可降低糖尿病肾病和慢性肾衰竭患者尿中肝型脂肪酸结合蛋白水平。
Diabetologia. 2007 Feb;50(2):490-2. doi: 10.1007/s00125-006-0545-4. Epub 2006 Dec 15.
5
Urinary liver-type fatty acid-binding protein is a predictor of mortality in individuals with type 2 diabetes.尿肝型脂肪酸结合蛋白是2型糖尿病患者死亡率的一个预测指标。
Diabet Med. 2021 Jun;38(6):e14527. doi: 10.1111/dme.14527. Epub 2021 Feb 3.
6
Adipocytokine zinc α2 glycoprotein (ZAG) as a novel urinary biomarker for normo-albuminuric diabetic nephropathy.脂肪细胞因子锌-α2 糖蛋白（ZAG）作为一种新型的尿生物标志物用于正常白蛋白尿型糖尿病肾病。
Diabet Med. 2012 Jul;29(7):945-9. doi: 10.1111/j.1464-5491.2011.03564.x.
7
Utility of serum and urinary transforming growth factor-beta levels as markers of diabetic nephropathy.血清和尿转化生长因子-β水平作为糖尿病肾病标志物的效用。
Nephron. 2000 Oct;86(2):234-5. doi: 10.1159/000045766.
8
Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients.尿小管标记物在 2 型糖尿病肾病早期的临床意义。
Diabetes Res Clin Pract. 2012 Aug;97(2):251-7. doi: 10.1016/j.diabres.2012.02.019. Epub 2012 Mar 21.
9
Glycopatterns of Urinary Protein as New Potential Diagnosis Indicators for Diabetic Nephropathy.尿蛋白糖型作为糖尿病肾病新的潜在诊断指标
J Diabetes Res. 2017;2017:5728087. doi: 10.1155/2017/5728087. Epub 2017 Mar 19.
10
Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.非白蛋白尿性蛋白尿作为 2 型糖尿病肾病早期小管损伤的生物标志物。
Diabetes Metab Res Rev. 2014 Nov;30(8):736-41. doi: 10.1002/dmrr.2546.

引用本文的文献

1
Urinary L-FABP: A Novel Biomarker for Evaluating Diabetic Nephropathy Onset and Progression. A Narrative Review.尿L-FABP：一种评估糖尿病肾病发病及进展的新型生物标志物。一篇叙述性综述。
Diabetes Ther. 2025 Jun;16(6):1107-1124. doi: 10.1007/s13300-025-01731-w. Epub 2025 Apr 3.
2
Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes.2型糖尿病患者皮肤自发荧光与以肝型脂肪酸结合蛋白尿排泄量定义的肾小管损伤之间的横断面和纵向关联
Biomedicines. 2023 Nov 10;11(11):3020. doi: 10.3390/biomedicines11113020.
3
Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease.
糖尿病肾病生物标志物在预测代谢相关脂肪性肝病中的意义
Biomedicines. 2023 Jul 7;11(7):1928. doi: 10.3390/biomedicines11071928.
4
Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis.尿肝型脂肪酸结合蛋白在糖尿病肾病中的表现：一项荟萃分析。
Front Med (Lausanne). 2022 Sep 2;9:914587. doi: 10.3389/fmed.2022.914587. eCollection 2022.
5
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.二肽基肽酶-4（DPP-4）抑制剂对糖尿病肾病患者肾脏损伤和血管钙化生物标志物的影响：一项随机对照试验。
J Diabetes Res. 2021 Oct 16;2021:7382620. doi: 10.1155/2021/7382620. eCollection 2021.
6
Relationship of urinary liver-type fatty acid-binding protein with cardiovascular risk factors in the Japanese population without chronic kidney disease: Sasayama study.在无慢性肾脏病的日本人群中，尿肝型脂肪酸结合蛋白与心血管危险因素的关系：酒井研究。
BMC Nephrol. 2021 May 21;22(1):189. doi: 10.1186/s12882-021-02398-8.
7
Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD).非白蛋白蛋白尿（NAP）作为糖尿病肾病（DKD）的补充标志物
Life (Basel). 2021 Mar 10;11(3):224. doi: 10.3390/life11030224.
8
Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients.评估尿L-FABP作为2型糖尿病患者糖尿病肾病早期标志物的价值。
J Med Biochem. 2020 Jan 23;39(2):224-230. doi: 10.2478/jomb-2019-0037.
9
FABP1 and FABP2 as markers of diabetic nephropathy.FABP1 和 FABP2 作为糖尿病肾病的标志物。
Int J Med Sci. 2020 Aug 27;17(15):2338-2345. doi: 10.7150/ijms.49078. eCollection 2020.
10
Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.循环脂肪酸结合蛋白 1（FABP1）与 2 型糖尿病患者的非酒精性脂肪性肝病。
Int J Med Sci. 2020 Jan 14;17(2):182-190. doi: 10.7150/ijms.40417. eCollection 2020.